Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Nektar eczema asset 'checked all of the boxes' in phase 2
The results set rezpeg up to become “a preferred second-line therapy” in atopic dermatitis.
Darren Incorvaia
Feb 10, 2026 10:55am
Amgen eyes lupus redemption while cancer candidate struggles
Feb 4, 2026 6:10am
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
Feb 2, 2026 3:01pm
Bright Minds anti-seizure candidate shines in phase 2 win
Jan 6, 2026 10:38am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Nektar claims ph. 2 alopecia success after excluding 4 patients
Dec 16, 2025 5:05pm
